Esperion Therapeutics (ESPR)
(Real Time Quote from BATS)
$2.03 USD
+0.14 (7.12%)
Updated Apr 23, 2024 11:52 AM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Price, Consensus and EPS Surprise
ESPR 2.03 +0.14(7.12%)
Will ESPR be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for ESPR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ESPR
Why Is Esperion Therapeutics (ESPR) Up 2% Since Last Earnings Report?
Zacks Industry Outlook Highlights United Therapeutics, Esperion Therapeutics., Heron Therapeutics, Lyra Therapeutics and Aldeyra Therapeutics
ESPR: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Small Drug Stocks to Buy From a Rebounding Industry
Esperion (ESPR) Q4 Earnings Top, Stock Up on Strong Revenues
Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates
Other News for ESPR
Esperion to Report First Quarter 2024 Financial Results on May 7
Applied Digital Reports Downbeat Results, Joins Nurix Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Understanding Serge Belanger’s Buy Rating for Esperion (ESPR): A Critical Analysis
Fly Intel: Pre-Market Movers